Finally, histone deacetylation can be inhibited by HDAC inhibitors (butyrate, trichostatin A and Suberoylanilide hydroxamic acid which is the FDA-approved Vorinostat) and have been shown in preclinical studies to selectively target cancer cells by inducing apoptosis, cell cycle arrest, suppression of tumour angiogenesis, metastasis and invasion at least partially through upregulating E-cadherin [267,296,297]. Here, CDH1 is linked to neoplasm.